Cyclic adenosine monophosphate phosphodiesterase (PDE (or cAMP phosphodiesterase; specific isoforms include PDE4, PDE7, etc.))

Cyclic adenosine monophosphate phosphodiesterases are a large family of enzymes responsible for the hydrolytic breakdown of cyclic AMP (cAMP) into inactive 5'-AMP. This enzymatic activity is crucial in terminating the biological actions of cAMP, a ubiquitous second messenger involved in regulating diverse cellular processes such as cardiac function, immune response, learning and memory. Multiple isoforms exist with distinct tissue distributions and substrate specificities; for example, PDE4 is highly selective for cAMP. These enzymes are important therapeutic targets because their inhibition can modulate signal transduction pathways implicated in diseases including inflammation, neurodegeneration, cardiovascular disorders, and cancer[1][2][5]. Selective inhibitors have been developed as drugs to treat conditions like chronic obstructive pulmonary disease and atopic dermatitis. **Note:** The term "cyclic adenosine monophosphate phosphodiesterase" refers to a family rather than a single protein; specificity may be required when considering drug development or research applications[1].

Other names

cAMP phosphodiesterase3',5'-cyclic adenosine monophosphate phosphodiesterasePhosphodiesterase (with isoform specification, e.g., PDE4)

Inhibition increases intracellular cAMP by preventing its breakdown, leading to enhanced signaling through cAMP-dependent pathways[1][2][5].